Search Results - "Witor, A"

Long‐term trends in HIV care entry: over 15 years of clinical experience from Poland by Siwak, E, Horban, A, Witak‐Jędra, M, Cielniak, I, Firląg‐Burkacka, E, Leszczyszyn‐Pynka, M, Witor, A, Muller, K, Bociąga‐Jasik, M, Kalinowska‐Nowak, A, Gąsiorowski, J, Szetela, B, Jabłonowska, E, Wójcik‐Cichy, K, Jankowska, J, Lemańska, M, Olczak, A, Grąbczewska, E, Grzeszczuk, A, Rogalska‐Plonska, M, Suchacz, M, Mikuła, T, Łojewski, W, Bielec, D, Kocbach, P, Błudzin, W, Parczewski, M

“…Introduction Delay in HIV diagnosis and consequently late care entry with low CD4 counts remain a major challenge for the control of the HIV/AIDS epidemic. The…”
Get full text

Metabolic abnormalities and cardiovascular risk in HIV-infected cohort of patients treated with protease inhibitors by Flisiak, R, Wiercińska-Drapało, A, Bociąga-Jasik, M, Barałkiewicz, G, Grzeszczuk, A, Olczak, A, Grąbczewska, E, Parczewski, M, Jabłonowska, E, Dąbrowska, M, Kozłowska, J, Mikuła, T, Witor, A, Gąsiorowski, J, Latarska-Smuga, D, Ścibiorski, C, Knysz, B

“…Abstract Aim Aim of this study was to evaluate cardiovascular risk in HIV-infected patients treated with atazanavir or lopinavir, both boosted with ritonavir,…”
Get full text

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial by Orkin, Chloe, Molina, Jean-Michel, Negredo, Eugenia, Arribas, José R, Eron, Joseph J, Van Landuyt, Erika, Lathouwers, Erkki, Hufkens, Veerle, Petrovic, Romana, Vanveggel, Simon, Ajana, F, Arribas, JR, Bailey, J, Benson, P, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, de Vente, J, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Fehr, J, Felizarta, F, Flamholc, L, Florence, E, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girard, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Huhn, G, Iribarren, JA, Jain, M, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Orkin, C, Osiyemi, O, Perez-Valero, I, Pineda, JA, Podzamczer, D, Portilla Sogorb, J, Post, F, Prelutsky, D, Pulido, F, Rachlis, A, Raffi, F, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Gil, I Santos, Scarsella, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Ustianowski, A, Van Wijngaerden, E, Vandercam, B, Walmsley, S, Wilkin, A, Witor, A, Yazdanpanah, Y

“…Simplified regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV. We investigated the efficacy and safety of…”
Get full text

Serum level of soluble intercellular adhesion molecule-1 in patients with acute viral hepatitis A or acute viral hepatitis B: lack of correlation with severity of the disease by Magiera, M, Kucharz, E J, Chelmicka, A, Moron-Swierszcz, J, Witor, A, Kotulska, A

“…Serum soluble ICAM-1 (sICAM-1) was found to be increased in patients with chronic hepatitis. The aim of the study was the evaluation of sICAM-1 dynamics in…”
Get more information

The role of adhesion molecule ICAM-1 in pathogenesis of Leśniowski's and Crohn's disease and ulcerative colitis by Magiera, M, Kucharz, E J, Chełmicka, A, Witor, A

Get more information

Tetanus in the Katowice district in the years 1976-1988 by Granicki, O, Czubówna, M, Chelmicka, A, Witor, A, Moroń-Swierszcz, J

“…Analysis of 89 tetanus cases that appeared in Katowice district in years 1976-1988 in comparison with country data has been made. Morbidity rate was lower than…”
Get more information